Apollo Peptide Sciences: Evidence & Transparency Review
A source-led review of Apollo Peptide Sciences, focusing on the evidence behind its batch testing rather than importing other publishers' vendor scores.
At a glance
| Criterion | Status | What we found |
|---|---|---|
| Batch-specific COAs | Strong public evidence | Current public product pages expose batch-linked testing documents and verification information. |
| Laboratory | Janoshik documented | Independent reviews have verified Janoshik Analytical reports with report/task identifiers and public verification keys. |
| Analytical scope | Purity + identity on sampled reports | Sampled reports include HPLC purity and mass-spectrometric identity/content information. The inspected public evidence does not establish a broad sterility/endotoxin panel across the catalogue. |
| Batch traceability | Good | Sampled reports connect products to specific batches and dated laboratory tasks. |
| Independent cross-checking | Growing | Multiple 2025–2026 Janoshik reports have been independently inspected by external reviewers. Community and long-term history remains limited because Apollo is a relatively young vendor. |
| Research-use positioning | Public | Apollo states products are for research purposes and not for human or veterinary use. |
| Final Peptide Choice Score | Not yet assigned | The evidence base is promising, but the score should wait for systematic inspection of current COAs and a clear distinction between purity/identity evidence and broader quality controls. |
1. What Apollo says it tests
Apollo Peptide Sciences states that products undergo independent third-party testing before being listed and that COAs and endotoxin reports are available. This is useful supplier-provided evidence, but our methodology requires checking the underlying documents rather than treating the claim itself as verification.
The public supplier material should therefore be read together with the actual laboratory reports. A broad statement about testing does not prove that every batch has the same analytical panel.
2. Janoshik evidence
Recent external audits have inspected multiple Apollo reports issued by Janoshik Analytical. One audit records BPC-157 10 mg, task 98641, dated January 14, 2026, at 99.887% purity; TB-500 10 mg, task 87815, dated November 13, 2025, at 99.760%; CJC-1295/Ipamorelin 5/5 mg, task 122907, dated March 20, 2026, with measured recovery of 5.35 mg and 5.24 mg; and semaglutide 5 mg, task 112106, dated March 16, 2026, with 99.222% reported in the inspected record.
Another recent review reports roughly 30 Janoshik reports on file and says the reports use public verification keys and include mass-spectrometric confirmation. These external audits are useful documentary cross-checks, but they are still secondary sources unless we inspect and verify the underlying laboratory records ourselves.
3. A useful distinction: purity is not the whole quality picture
The strongest public Apollo evidence concerns identity, content and purity. That is valuable, but it should not be converted into a blanket statement that a batch is sterile, endotoxin-free or otherwise suitable for human use.
One external audit specifically notes that the inspected Janoshik reports did not document endotoxin or sterility testing, while Apollo's own about page says endotoxin reports are provided. We therefore record this as an open document-verification question rather than choosing one source by assumption: the underlying Apollo endotoxin reports should be inspected before we mark that criterion as verified.
4. Current evidence strengths
- Multiple dated, lot-specific Janoshik reports are publicly discussed and independently checked by external reviewers.
- Sampled reports show high purity results for several compounds, including BPC-157, TB-500 and semaglutide.
- Verification keys and report/task identifiers create a useful documentary trail.
- The company publishes its research-use positioning and describes its testing process openly.
Limitations & open questions
- Apollo is a relatively young vendor, so long-term batch-to-batch history is limited.
- The publicly inspected evidence is concentrated in a subset of products rather than the entire catalogue.
- We need to inspect the underlying endotoxin reports before treating Apollo's broad endotoxin claim as verified.
- Purity and identity results do not by themselves establish sterility, endotoxin status, chain of custody or suitability for human use.
- External publishers use different scoring systems; Peptide Choice Guide will not copy those scores.
5. Why we are withholding a numerical score
Apollo currently has a stronger documentary signal than a supplier with only generic testing claims, but assigning a final number before we inspect a systematic sample of current reports would create false precision.
We will keep analytical evidence, documentation coverage, laboratory verification and operational track record separate. A strong purity result will improve the evidence record for that batch; it will not automatically improve every other criterion.
Sources reviewed
| Evidence | Source | Role |
|---|---|---|
| Company testing statement | Apollo Peptide Sciences — About Us | Supplier-provided evidence |
| 2026 laboratory audit | Peptide Source Review — Apollo | Secondary verification of sampled COAs |
| 2026 independent review | Project Biohacking — Apollo review | Secondary cross-check and limitations |
| Vendor scorecard context | Peptide Bureau — Apollo review | Secondary source; its score is not imported into ours |
Affiliate disclosure
Peptide Choice Guide may have a commercial/affiliate relationship with Apollo Peptides. Any such relationship is disclosed separately and does not increase the editorial score or change the evidence standard applied to Apollo.